Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion

by Xie, Z., Choong, P.F., Poon, L.F., Zhou, J., Jasinghe, V.J., Palaniyandi, S.
Published 2011

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

by Jasinghe, V.J., Xie, Z., Zhou, J., Khng, J., Poon, L.-F., Senthilnathan, P., Chen, C.-S., Albert, D.H., Davidsen, S.K.
Published 2011

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

by Zhou, J., Bi, C., Janakakumara, J.V., Liu, S.-C., Chng, W.-J., Tay, K.-G., Poon, L.-F., Xie, Z., Palaniyandi, S., Chen, C.-S., Yu, H., Glaser, K.B., Albert, D.H., Davidsen, S.K.
Published 2011

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor

by Zhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K.
Published 2011

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor

by Zhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K.
Published 2011

Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity

by Ooi, W.F, Xing, M, Xu, C, Yao, X, Ramlee, M.K, Lim, M.C, Cao, F, Lim, K, Babu, D, Poon, L.-F, Lin Suling, J, Qamra, A, Irwanto, A, Qu Zhengzhong, J, Nandi, T, Lee-Lim, A.P, Chan, Y.S, Tay, S.T, Lee, M.H, Davies, J.O.J, Wong, W.K, Soo, K.C, Chan, W.H, Ong, H.S, Chow, P, Wong, C.Y, Rha, S.Y, Liu, J, Hillmer, A.M, Hughes, J.R, Rozen, S, Teh, B.T, Fullwood, M.J, Li, S, Tan, P
Published 2020